14,300 Shares in Evolent Health, Inc (EVH) Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new position in Evolent Health, Inc (NYSE:EVH) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 14,300 shares of the technology company’s stock, valued at approximately $363,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in EVH. Russell Investments Group Ltd. acquired a new position in shares of Evolent Health during the fourth quarter worth $1,178,000. State Street Corp raised its position in shares of Evolent Health by 5.2% in the fourth quarter. State Street Corp now owns 250,000 shares of the technology company’s stock worth $3,699,000 after buying an additional 12,339 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Evolent Health by 134.7% in the fourth quarter. AQR Capital Management LLC now owns 25,657 shares of the technology company’s stock worth $380,000 after buying an additional 14,723 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Evolent Health by 5.1% in the fourth quarter. Teachers Advisors LLC now owns 25,119 shares of the technology company’s stock worth $372,000 after buying an additional 1,211 shares in the last quarter. Finally, Highbridge Capital Management LLC acquired a new position in shares of Evolent Health during the fourth quarter worth $1,390,000. 68.77% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Evolent Health, Inc (NYSE EVH) opened at 26.85 on Wednesday. Evolent Health, Inc has a 1-year low of $14.50 and a 1-year high of $27.50. The company’s 50 day moving average price is $25.71 and its 200-day moving average price is $21.98. The firm’s market cap is $1.55 billion.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, May 9th. The technology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The business had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $104.38 million. During the same quarter in the prior year, the firm posted ($0.16) EPS. The business’s quarterly revenue was up 116.2% compared to the same quarter last year. Equities analysts expect that Evolent Health, Inc will post ($0.41) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “14,300 Shares in Evolent Health, Inc (EVH) Acquired by Fox Run Management L.L.C.” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://transcriptdaily.com/2017/07/19/14300-shares-in-evolent-health-inc-evh-acquired-by-fox-run-management-l-l-c.html.

EVH has been the topic of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a report on Thursday, April 13th. Zacks Investment Research raised Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a report on Wednesday, May 3rd. TheStreet raised Evolent Health from a “d” rating to a “c-” rating in a report on Monday, May 22nd. Robert W. Baird initiated coverage on Evolent Health in a report on Thursday, June 1st. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $32.00 price objective (up previously from $30.00) on shares of Evolent Health in a report on Monday, June 19th. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. Evolent Health currently has a consensus rating of “Buy” and a consensus price target of $29.73.

In other Evolent Health news, insider Tpg Growth Ii Advisors, Inc. sold 4,279,325 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $25.87, for a total value of $110,706,137.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Nicholas Mcgrane sold 1,667 shares of the business’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $25.42, for a total value of $42,375.14. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,552,342 shares of company stock valued at $261,328,655. Insiders own 8.79% of the company’s stock.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply